Gelesis Holdings, Inc. (GLSHQ) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
501 BOYLSTON STREET, SUITE 6102 BOSTON, MA 02116 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 7,412 | 221 | 492 | |||
| Cash and cash equivalents | 7,412 | 221 | 492 | |||
| Receivables | 6,831 | |||||
| Inventory, net of allowances, customer advances and progress billings | 6,865 | |||||
| Inventory | 6,865 | |||||
| Prepaid expense | 314 | 14 | 66 | |||
| Other undisclosed current assets | 2,074 | |||||
| Total current assets: | 23,496 | 235 | 558 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 1,520 | |||||
| Property, plant and equipment | 59,335 | |||||
| Intangible assets, net (including goodwill) | 13,413 | |||||
| Intangible assets, net (excluding goodwill) | 13,413 | |||||
| Asset, held-in-trust | 276,207 | 276,209 | ||||
| Other noncurrent assets | 5,560 | |||||
| Total noncurrent assets: | 79,828 | 276,207 | 276,209 | |||
| TOTAL ASSETS: | 103,324 | 276,442 | 276,767 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 14,599 | 21,806 | 1,631 | |||
| Accounts payable | 4,131 | |||||
| Accrued liabilities | 10,468 | 21,806 | 1,631 | |||
| Deferred revenue | 27,793 | |||||
| Debt | 7,954 | |||||
| Due to related parties | 2,142 | |||||
| Other undisclosed current liabilities | 25,858 | |||||
| Total current liabilities: | 78,346 | 21,806 | 1,631 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 25,342 | |||||
| Long-term debt, excluding current maturities | 25,342 | |||||
| Liabilities, other than long-term debt | 11,539 | |||||
| Deferred revenue | 9,544 | |||||
| Financial instruments subject to mandatory redemption, settlement terms, share value, amount | 130 | |||||
| Other liabilities | 898 | |||||
| Operating lease, liability | 967 | |||||
| Other undisclosed noncurrent liabilities | 563 | |||||
| Total noncurrent liabilities: | 37,444 | |||||
| Other undisclosed liabilities | 32,159 | 39,762 | ||||
| Total liabilities: | 115,790 | 53,965 | 41,393 | |||
| Temporary equity, carrying amount | 12,590 | 276,000 | 276,033 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | (25,056) | (53,523) | (40,659) | |||
| Common stock | 7 | |||||
| Additional paid in capital | 297,468 | |||||
| Accumulated other comprehensive income | 104 | |||||
| Accumulated deficit | (322,635) | (53,524) | (40,660) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | ||||
| Total equity: | (25,056) | (53,523) | (40,659) | |||
| TOTAL LIABILITIES AND EQUITY: | 103,324 | 276,442 | 276,767 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Revenues | 25,767 | ||||
| Cost of revenue | (27,558) | (20,674) | (2,426) | ||
| Cost of goods and services sold | (27,558) | ||||
| Gross profit: | (1,791) | (20,674) | (2,426) | ||
| Operating expenses | (120,015) | ||||
| Operating loss: | (121,806) | (20,674) | (2,426) | ||
| Nonoperating income (expense) | 4,664 | 7,776 | (12,869) | ||
| Other nonoperating income | 4,664 | ||||
| Interest and debt expense | (991) | ||||
| Loss from continuing operations before equity method investments, income taxes: | (118,133) | (12,898) | (15,295) | ||
| Other undisclosed income from continuing operations before income taxes | 62,833 | ||||
| Loss from continuing operations before income taxes: | (55,300) | (12,898) | (15,295) | ||
| Income tax expense (benefit) | (480) | (29) | 466 | ||
| Other undisclosed loss from continuing operations | |||||
| Loss from continuing operations: | (55,780) | (12,927) | (14,829) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (12,927) | (14,829) | ||
| Other undisclosed net income (loss) | 25,825 | (466) | |||
| Net income (loss): | (55,780) | 12,898 | (15,295) | ||
| Net loss attributable to noncontrolling interest | (1,095) | ||||
| Other undisclosed net income (loss) attributable to parent | 1,095 | (25,796) | |||
| Net loss attributable to parent: | (55,780) | (12,898) | (15,295) | ||
| Preferred stock dividends and other adjustments | (37,934) | ||||
| Other undisclosed net loss available to common stockholders, basic | (1,348) | (28) | |||
| Net loss available to common stockholders, diluted: | (95,062) | (12,898) | (15,323) | ||
Comprehensive Income ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|
| Net income (loss): | (55,780) | 12,898 | (15,295) | ||
| Comprehensive income (loss): | (55,780) | 12,898 | (15,295) | ||
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (1,095) | ||||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 980 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (55,895) | 12,898 | (15,295) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.